Alcohol consumption and breast cancer risk in Japanese women: the Miyagi Cohort study.

Abstract:

:Alcohol consumption is known to be a risk factor for breast cancer in Western countries, but few epidemiologic data have been available in Japan. This population-based prospective cohort study evaluated the associations of alcohol consumption with breast cancer risk in a Japanese population. A total of 19,227 women aged 40-64 years were followed from 1990 to 2003. During 246,703 person-years of follow-up, 241 breast cancer cases were identified. Hazard ratios (HRs) were estimated by the Cox proportional-hazard regression model. After adjustment for potential risk factors of breast cancer and nutritional factors, the HR and 95% confidence interval (CI) for current drinkers was 1.00 (0.74-1.34) compared with never drinkers. According to the amount of alcohol intake per day, a higher amount (≥15.0 g/day) had no significant relation to breast cancer risk (HR = 0.87, 95% CI: 0.40-1.91; P for trend = 0.85). Age upon starting to drink, and the frequency of drinking, were not associated with breast cancer risk. In analysis stratified according to exogenous female hormone use, a higher alcohol intake (≥15.0 g/day) was associated with an increased risk of breast cancer among hormone users (HR = 1.67, 95% CI: 0.17-16.73); however, this was not statistically significant. Stratification according to folate intake with energy adjustment (<219, ≥ 219 μg/day) found that breast cancer risk tended to increase with increasing alcohol consumption among women with a low intake of folate (P for trend = 0.09). Our findings suggest that alcohol consumption has no overall effect on breast cancer risk among Japanese women, whereas nutritional factors such as folate intake may modify the alcohol-breast cancer risk relationship.

authors

Kawai M,Minami Y,Kakizaki M,Kakugawa Y,Nishino Y,Fukao A,Tsuji I,Ohuchi N

doi

10.1007/s10549-011-1381-x

subject

Has Abstract

pub_date

2011-08-01 00:00:00

pages

817-25

issue

3

eissn

0167-6806

issn

1573-7217

journal_volume

128

pub_type

杂志文章
  • The prognostic value of NRF2 in breast cancer patients: a systematic review with meta-analysis.

    abstract:PURPOSE:Nuclear factor E2-related factor 2 (NRF2) is a transcription factor that plays a major role in the regulation of intracellular antioxidant response. The effect of NRF2 overexpression in many malignancies is still unclear and recent meta-analysis correlated NRF2 overexpression with poor prognosis in a variety of...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,meta分析

    doi:10.1007/s10549-019-05494-4

    authors: Almeida M,Soares M,Ramalhinho AC,Moutinho JF,Breitenfeld L,Pereira L

    更新日期:2020-02-01 00:00:00

  • HER2+ breast cancer treatment and cardiotoxicity: monitoring and management.

    abstract:BACKGROUND:Breast cancer is a leading cause of death for women worldwide, with incidence increasing in lower-income countries. For patients with human epidermal growth factor receptor-2-positive (HER2+) breast cancer, widespread availability of several agents targeting the HER2 receptor has resulted in survival gains o...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,评审

    doi:10.1007/s10549-019-05303-y

    authors: Jerusalem G,Lancellotti P,Kim SB

    更新日期:2019-09-01 00:00:00

  • Variation in breast cancer risk with mutation position, smoking, alcohol, and chest X-ray history, in the French National BRCA1/2 carrier cohort (GENEPSO).

    abstract::Germline mutations in BRCA1/2 confer a high risk of breast cancer (BC), but the magnitude of this risk varies according to various factors. Although controversial, there are data to support the hypothesis of allelic-risk heterogeneity. We assessed variation in BC risk according to the location of mutations recorded in...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-011-1655-3

    authors: Lecarpentier J,Noguès C,Mouret-Fourme E,Stoppa-Lyonnet D,Lasset C,Caron O,Fricker JP,Gladieff L,Faivre L,Sobol H,Gesta P,Frenay M,Luporsi E,Coupier I,GENEPSO.,Lidereau R,Andrieu N

    更新日期:2011-12-01 00:00:00

  • Hypomethylation of the MMP7 promoter and increased expression of MMP7 distinguishes the basal-like breast cancer subtype from other triple-negative tumors.

    abstract::Identification of novel targets for the treatment of basal-like breast cancer is essential for improved outcomes in patients with this disease. This study investigates the association of MMP7 expression and MMP7 promoter methylation with subtype and outcome in breast cancer patient cohorts. Immunohistochemical analysi...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-014-2989-4

    authors: Sizemore ST,Sizemore GM,Booth CN,Thompson CL,Silverman P,Bebek G,Abdul-Karim FW,Avril S,Keri RA

    更新日期:2014-07-01 00:00:00

  • Pharmacology of aminoglutethimide: structure/activity relationships and receptor interactions.

    abstract::The structure/activity relationships for inhibition of aromatase and cholesterol side-chain cleavage enzyme (CSCC) by aminoglutethimide and some of its analogues are reviewed. Although more effective against aromatase than CSCC, aminoglutethimide markedly inhibits both enzymes. Optimal competitive antagonism of aromat...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:

    authors: Nicholls PJ,Daly MJ,Smith HJ

    更新日期:1986-01-01 00:00:00

  • Estrogen-regulated non-reproductive behaviors and breast cancer risk: animal models and human studies.

    abstract::The possible role of personality patterns and psychosocial factors in breast cancer has been studied extensively, through both human and animal experiments. The data are conflicting, and the conclusions controversial. This review will serve two purposes. First, we present evidence that behavioral patterns most commonl...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,评审

    doi:10.1023/a:1005964511134

    authors: Hilakivi-Clarke L

    更新日期:1997-11-01 00:00:00

  • Recurrent germline mutations in BRCA1 and BRCA2 genes in high risk families in Israel.

    abstract::The spectrum of germline mutations among Jewish non Ashkenazi high risk breast/ovarian cancer families includes a few predominant mutations in BRCA1 (185delAG and Tyr978X) and BRCA2 (8765delAG). A few additional recurring mutations [A1708E, 981delAT, C61G (BRCA1) R2336P, and IVS2 + 1G > A (BRCA2)] have been reported i...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-012-2006-8

    authors: Laitman Y,Simeonov M,Herskovitz L,Kushnir A,Shimon-Paluch S,Kaufman B,Zidan J,Friedman E

    更新日期:2012-06-01 00:00:00

  • The impact of the pathological lymph node status on adjuvant systemic treatment recommendations in clinically node negative breast cancer patients.

    abstract::Several independent randomized controlled trials are initiated to investigate whether sentinel lymph node biopsy can be safely omitted in clinically node negative breast cancer patients with negative axillary ultrasound findings, who are treated with breast conserving therapy. A consequence of omitting sentinel lymph ...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,随机对照试验

    doi:10.1007/s10549-013-2822-5

    authors: van Roozendaal LM,Schipper RJ,Van de Vijver KK,Haekens CM,Lobbes MB,Tjan-Heijnen VC,de Boer M,Smidt ML

    更新日期:2014-02-01 00:00:00

  • Increased hematopoietic progenitor cell maintenance in long-term bone marrow cultures containing minimal numbers of contaminating breast cancer cells.

    abstract::The maintenance of hematopoietic progenitor cells as assayed in the mixed colony (CFU-GEMM) assay in human long-term bone marrow cultures was compared between normal allogeneic marrow transplantation donor collections and those from candidates for high-dose therapy and autologous bone marrow transplantation (ABMT). To...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1023/a:1005732531318

    authors: Mann SL,Joshi SS,Crouse DA,Armitage JO,Kessinger A,Weisenburger DD,Vaughan WP,Sharp JG

    更新日期:1997-06-01 00:00:00

  • Biweekly administration of gemcitabine and vinorelbine as first line therapy in elderly advanced breast cancer.

    abstract:BACKGROUND:Gemcitabine and Vinorelbine both as a single agent or associated are active in advanced breast cancer patients as second line therapy, with low toxicity. In the elderly patients polichemotherapy is difficult for co-morbidity, but results with monotherapy are fewer. The use of this association as first line c...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-004-1000-1

    authors: Dinota A,Bilancia D,Romano R,Manzione L

    更新日期:2005-01-01 00:00:00

  • Comparison among different classification systems regarding the pathological response of preoperative chemotherapy in relation to the long-term outcome.

    abstract::Neoadjuvant chemotherapy (NAC) is increasingly used for operable disease. However there are several pathological response classification systems and the correlation between the pathological response to NAC according to each system and the patient outcome is still under debate. From 1998 to 2006, 370 primary breast can...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-008-9935-2

    authors: Shien T,Shimizu C,Seki K,Shibata T,Hojo T,Ando M,Kohno T,Katsumata N,Akashi-Tanaka S,Kinoshita T,Fujiwara Y

    更新日期:2009-01-01 00:00:00

  • A GINECO randomized phase II trial of two capecitabine and weekly paclitaxel schedules in metastatic breast cancer.

    abstract::To determine whether capecitabine schedule adaptation improves the tolerability of capecitabine-paclitaxel combination therapy for metastatic breast cancer (MBC), patients with anthracycline-pretreated HER2-negative MBC were randomized to either arm A (21-day cycles: capecitabine 1,000 mg/m(2) twice daily, days 1-14; ...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,随机对照试验

    doi:10.1007/s10549-011-1776-8

    authors: Lortholary A,Hardy-Bessard AC,Bachelot T,de Rauglaudre G,Alexandre J,Bourgeois H,Jaubert D,Paraiso D,Largillier R

    更新日期:2012-01-01 00:00:00

  • Factors predicting in-breast tumor recurrence after breast-conserving surgery.

    abstract:PURPOSE:The main objectives of this study were to identify risk factors for local in-breast tumor recurrence after breast-conservation and to evaluate the impact of IBTR (in-breast tumor recurrence) on overall survival. METHODS:A total of 335 consecutive patients with 346 invasive and in situ breast cancers were treat...

    journal_title:Breast cancer research and treatment

    pub_type: 临床试验,杂志文章

    doi:10.1007/s10549-008-0187-y

    authors: Mechera R,Viehl CT,Oertli D

    更新日期:2009-07-01 00:00:00

  • Diagnostic ability of different human milk fat globule antigens in breast cancer.

    abstract::Human mammary epithelial antigens (HME-Ags) are released into the circulation by breast tumors and not by normal breast tissue (Proc. Natl. Acad. Sci. USA 74: 582-586, 1977). This characteristic made them valuable, together with other breast cancer related antigens later identified, to develop immunoassays useful in t...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/BF01806353

    authors: Ceriani RL,Blank EW,Rosenbaum EH,Ben Zeev D,Lowitz RS,Johansen L,Trujillo T

    更新日期:1990-05-01 00:00:00

  • Age-of-onset heterogeneity in hereditary breast cancer: minimal clues for diagnosis.

    abstract::Knowledge of the family history of cancer may significantly influence diagnosis and surgical management. Hereditary breast cancer (HBC) is common and accounts for approximately 9% of the total breast cancer burden. The pattern of HBC's natural history, including age of onset, increased incidence of bilaterality, integ...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/BF01811240

    authors: Lynch HT,Conway T,Fitzgibbons R Jr,Schreiman J,Watson P,Marcus J,Fitzsimmons ML,Lynch JF

    更新日期:1988-12-01 00:00:00

  • Adherence to adjuvant hormone therapy in low-income women with breast cancer: the role of provider-patient communication.

    abstract::To assess the impact of patient-provider communication on adherence to tamoxifen (TAM) and aromatase inhibitors (AIs) 36 months after breast cancer (BC) diagnosis in a low-income population of women. California statewide surveys were conducted among 921 low-income women with BC at 6, 18, and 36 months after BC diagnos...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-012-2387-8

    authors: Liu Y,Malin JL,Diamant AL,Thind A,Maly RC

    更新日期:2013-02-01 00:00:00

  • Cognitive function and discontinuation of adjuvant hormonal therapy in older breast cancer survivors: CALGB 369901 (Alliance).

    abstract:PURPOSE:To investigate the effects of cognitive function on discontinuation of hormonal therapy in breast cancer survivors ages 65+ ("older"). METHODS:Older breast cancer survivors with invasive, non-metastatic disease, and no reported cognitive difficulties were recruited from 78 Alliance sites between 2004 and 2011....

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,多中心研究

    doi:10.1007/s10549-017-4353-y

    authors: Bluethmann SM,Alfano CM,Clapp JD,Luta G,Small BJ,Hurria A,Cohen HJ,Sugarman S,B Muss H,Isaacs C,Mandelblatt JS

    更新日期:2017-10-01 00:00:00

  • A phase II trial of cyclophosphamide, epirubicin and vinorelbine in the treatment of advanced breast cancer.

    abstract:BACKGROUND:Vinorelbine (Navelbin; N) has proven to be active in patients with advanced breast cancer (ABC) and cyclophosphamide (C) and epirubicin (Epiadriamycin: E) are still among the main cytostatic agents against this tumor. On this basis was carried out a study to determine the activity and toxicity of the combina...

    journal_title:Breast cancer research and treatment

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1023/a:1006477109230

    authors: Esteban E,de Sande G,Puertas J,Fra J,Palacio I,Vieitez JM,Fernández JL,Muñiz I,Modollel A,Carrasco J,Sala M,Lacave AJ

    更新日期:2000-07-01 00:00:00

  • Estrogen responsiveness of IBEP-2, a new human cell line derived from breast carcinoma.

    abstract::IBEP-2, an established cell line recently derived from breast carcinoma, was characterized with regard to estrogen receptor (ER) expression, cell mitogenic response to estrogenic stimulation and sensitivity to antiestrogens. In addition, we examined ER modulation following binding of agonist and antagonists, and the E...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1023/B:BREA.0000032922.87541.31

    authors: Journé F,Body JJ,Leclercq G,Nonclercq D,Laurent G

    更新日期:2004-07-01 00:00:00

  • Use of dried blood spots for the determination of serum concentrations of tamoxifen and endoxifen.

    abstract::The anti-estrogenic effect of tamoxifen is suggested to be mainly attributable to its metabolite (Z)-endoxifen, and a minimum therapeutic threshold for (Z)-endoxifen in serum has been proposed. The objective of this research was to establish the relationship between dried blood spot (DBS) and serum concentrations of t...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-014-2999-2

    authors: Jager NG,Rosing H,Schellens JH,Beijnen JH,Linn SC

    更新日期:2014-07-01 00:00:00

  • Impact of videotaped information on frequency and confidence of breast self-examination.

    abstract:BACKGROUND:Videotaped education materials to teach breast self-examination (BSE) are used worldwide. However, evaluation of videotaped BSE instructions is lacking. METHODS:Premenopausal women (mean age 33.4+/-11.2 years) without history of breast cancer were approached to participate in this experimental study and ran...

    journal_title:Breast cancer research and treatment

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1023/a:1015264103561

    authors: Janda M,Stanek C,Newman B,Obermair A,Trimmel M

    更新日期:2002-05-01 00:00:00

  • Chemotherapy responsiveness of human breast tumors in the 6-day subrenal capsule assay: an update.

    abstract::Feasibility of utilizing the 6-day subrenal capsule (SRC) assay to screen drugs against fresh surgical explants of human tumors was confirmed by testing six clinically active chemotherapeutic agents against 141 human breast cancers. Response rates of the six drugs obtained in the assay compared favorably with clinical...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/BF01806232

    authors: Bogden AE,Costanza ME,Reich SD,Griffin TW,Cobb WR

    更新日期:1983-01-01 00:00:00

  • Significant inter- and intra-laboratory variation in grading of ductal carcinoma in situ of the breast: a nationwide study of 4901 patients in the Netherlands.

    abstract:PURPOSE:A considerable part of ductal carcinoma in situ (DCIS) lesions may never progress into invasive breast cancer. However, standard treatment consists of surgical excision. Trials aim to identify a subgroup of low-risk DCIS patients that can safely forgo surgical treatment based on histologic grade, which highligh...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-018-05082-y

    authors: van Dooijeweert C,van Diest PJ,Willems SM,Kuijpers CCHJ,Overbeek LIH,Deckers IAG

    更新日期:2019-04-01 00:00:00

  • Andrographolide prevents human breast cancer-induced osteoclastic bone loss via attenuated RANKL signaling.

    abstract::Bone metastasis is a common and serious complication in advanced cancers such as breast cancer, prostate cancer, and multiple myeloma. Agents that prevent bone loss could be used to develop an alternative therapy for bone metastasis. RANKL, a member of the tumor necrosis factor superfamily, has been shown to play a si...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-014-2844-7

    authors: Zhai Z,Qu X,Yan W,Li H,Liu G,Liu X,Tang T,Qin A,Dai K

    更新日期:2014-02-01 00:00:00

  • Postoperative complications and survival of elderly breast cancer patients: a FOCUS study analysis.

    abstract::Old age is associated with comorbidity and decreased functioning which influences treatment decisions in elderly breast cancer patients. The purpose of this study was to identify risk factors for complications after breast cancer surgery in elderly patients, and to assess mortality in patients with postoperative compl...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-013-2462-9

    authors: de Glas NA,Kiderlen M,Bastiaannet E,de Craen AJ,van de Water W,van de Velde CJ,Liefers GJ

    更新日期:2013-04-01 00:00:00

  • Characterization of chemotherapy-induced peripheral neuropathy using patient-reported outcomes and quantitative sensory testing.

    abstract:PURPOSE:Chemotherapy-induced peripheral neuropathy (CIPN) is a common, debilitating side effect in cancer survivors. This study aimed to assess the characteristics of quantitative sensory testing (QST) and its correlation with patient-reported outcomes (PROs) in cancer patients with and without CIPN. METHODS:We conduc...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-020-06079-2

    authors: Zhi WI,Baser RE,Kwon A,Chen C,Li SQ,Piulson L,Seluzicki C,Panageas KS,Harte SE,Mao JJ,Bao T

    更新日期:2021-01-28 00:00:00

  • Assessing cost-utility of predictive biomarkers in oncology: a streamlined approach.

    abstract::Evaluation of cost-utility is critical in assessing the medical utility of predictive or prognostic biomarkers. Current methods involve complex state-transition models, requiring comprehensive data inputs. We propose a simplified decision-analytic tool to explore the relative effect of factors contributing to the cost...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-016-3677-3

    authors: Safonov A,Wang S,Gross CP,Agarwal D,Bianchini G,Pusztai L,Hatzis C

    更新日期:2016-01-01 00:00:00

  • Photodynamic therapy as an effective therapeutic approach in MAME models of inflammatory breast cancer.

    abstract::Photodynamic therapy (PDT) is a minimally invasive, FDA-approved therapy for treatment of endobronchial and esophageal cancers that are accessible to light. Inflammatory breast cancer (IBC) is an aggressive and highly metastatic form of breast cancer that spreads to dermal lymphatics, a site that would be accessible t...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-015-3618-6

    authors: Aggarwal N,Santiago AM,Kessel D,Sloane BF

    更新日期:2015-11-01 00:00:00

  • Histone methyltransferases regulate the transcriptional expression of ERα and the proliferation of tamoxifen-resistant breast cancer cells.

    abstract:PURPOSE:Although tamoxifen remains the frontline treatment for ERα-positive breast cancers, resistance to this drug limits its clinical efficacy. Most tamoxifen-resistant patients retain ERα expression which may support growth and progression of breast cancers. Therefore, we investigated epigenetic regulation of ERα th...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-019-05517-0

    authors: Kim SS,Lee MH,Lee MO

    更新日期:2020-02-01 00:00:00

  • Prevalence of BRCA1 and BRCA2 mutations in breast cancer patients from Brazil.

    abstract::The contribution of BRCA1 and BRCA2 to breast cancer incidence in Brazil has not yet been explored. In order to estimate the proportion of breast cancers due to BRCA1 and BRCA2 mutations in Brazil, we conducted a study of unselected breast cancer patients from Rio de Janeiro, Brazil. We enrolled 402 women with breast ...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-006-9378-6

    authors: Gomes MC,Costa MM,Borojevic R,Monteiro AN,Vieira R,Koifman S,Koifman RJ,Li S,Royer R,Zhang S,Narod SA

    更新日期:2007-07-01 00:00:00